ArticleNature nanotechnology2019
A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain.
Open access · greenAbstract read
In one paragraph
Article in Nature nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 157 citations in OpenAlex.
- Dual-Targeted Inhibition of PARNanomaterials (Basel, Switzerland) · 2026Article
- Development of pH-Sensitive β‑Adrenergic Receptor Antagonists.ACS pharmacology & translational science · 2026Article
- Recent advances in nanomaterial-based strategies for chronic pain alleviation.Materials today. Bio · 2026Review
- MMP1 and PRSS23 induce PARCommunications biology · 2026Article
- Parallel CRISPR screens reveal pathways controlling the cell surface levels of the attractant receptor FPR1.Communications biology · 2026Article
- The contribution of endocytic mediators to itch transmission.bioRxiv : the preprint server for biology · 2026Article
- A nano-structured reporter for high-sensitivity contaminant detection in groundwater.Nature communications · 2026Article
- The contribution of endocytic mediators to itch transmission.Frontiers in molecular neuroscience · 2026Article
- Drug-assisted synthesis of copper nanoparticles and their induction of cuproptosis and necrosis for breast cancer therapy.Journal of Zhejiang University. Science. B · 2025Article
- Nanomedicines targeting protease-activated receptor 2 in endosomes provide sustained analgesia.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025Review
- Microglia are prominent producers of inflammatory cytokines during the hyperacute phase of ischemic stroke.Communications biology · 2025Article
- Chemical biology approaches to resolve the subcellular GPCR signaling landscape.Nature chemical biology · 2025Review
- Emerging treatments for chronic neuropathic pain from a cross-disease perspective: developments and applications of nanomaterials.The journal of headache and pain · 2025Review
- Pain Signaling by GPCRs and RTKs.Trends in pharmacological sciences · 2025Review
- PARBiomaterials · 2025Article
- Pathophysiology-Directed Engineering of a Combination Nanoanalgesic for Neuropathic Pain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Activation of the proton-sensing GPCR, GPR65 on fibroblast-like synoviocytes contributes to inflammatory joint pain.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors.Nature reviews. Nephrology · 2024Review
- Microenvironment-responsive nanomedicines: a promising direction for tissue regeneration.Military Medical Research · 2024Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 2 countries.
Paulina D Ramírez-GarcíaMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0003-0971-3501
Jeffri S RetamalMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Priyank ShenoyMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Wendy ImlachMonash Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-7521-9969
Matthew SykesMonash Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia.
Nghia TruongMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0001-9900-2644
Luis ConstandilLaboratory of Neurobiology, Center for the Development of Nanoscience and Nanotechnology (CEDENNA), University of Santiago de Chile, Santiago, Chile.ORCID http://orcid.org/0000-0002-2504-0119
Teresa PelissierLaboratory of Neurobiology, Center for the Development of Nanoscience and Nanotechnology (CEDENNA), University of Santiago de Chile, Santiago, Chile.
Cameron J NowellMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Song Y KhorMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Louis M LayaniMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Chris LumbMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Daniel P PooleMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0002-6168-8422
TinaMarie LieuMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Gregory D StewartMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Quynh N MaiMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Dane D JensenDepartments of Surgery and Pharmacology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University in the City of New York, New York , NY, USA.
Rocco LatorreDepartments of Surgery and Pharmacology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University in the City of New York, New York , NY, USA.
Nicole N ScheffBluestone Centre for Clinical Research, New York University College of Dentistry, New York, NY, USA.
Brian L SchmidtBluestone Centre for Clinical Research, New York University College of Dentistry, New York, NY, USA.
John F QuinnMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Michael R WhittakerMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Nicholas A VeldhuisMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. nicholas.veldhuis@monash.edu.
Thomas P DavisMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. thomas.p.davis@monash.edu.ORCID http://orcid.org/0000-0003-2581-4986
Nigel W BunnettMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. nwb2@nyu.edu.ORCID http://orcid.org/0000-0003-3367-0644
Australian Research Council · AUAustralian Regenerative Medicine Institute · AUColumbia University · USMonash University · AUNew York University · US
Funding
Targeting Endosomal Receptors for Treatment of Chronic PainR01DE029951 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2020 to 2024
$4.7MProtease/PAR2/TRPV4 Axis and Oral Cancer PainR01DE026806 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2022
$3.9MEndosomal Platforms for Signaling PainR01NS102722 · NINDS · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Brian L Schmidt · 2017 to 2026
$3.4MTrafficking-Dependent Signaling of Pain by Protease-Activated ReceptorsR01DK118971 · NIDDK · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2021
$3.2MNIDCR NIH HHS R01 DE026806NIDCR NIH HHS R01 DE029951NIDDK NIH HHS R01 DK118971NINDS NIH HHS R01 NS102722
Abstract
Nanoparticle-mediated drug delivery is especially useful for targets within endosomes because of the endosomal transport mechanisms of many nanomedicines within cells. Here, we report the design of a pH-responsive, soft polymeric nanoparticle for the targeting of acidified endosomes to precisely inhibit endosomal signalling events leading to chronic pain. In chronic pain, the substance P (SP) neurokinin 1 receptor (NK
Indexed as
AnimalsAprepitantCell LineChronic PainDelayed-Action PreparationsDrug Delivery SystemsEndosomesHEK293 CellsHumansHydrogen-Ion ConcentrationMaleMice, Inbred C57BLNanoparticlesNeurokinin-1 Receptor AntagonistsRatsReceptors, Neurokinin-1AprepitantDelayed-Action PreparationsNeurokinin-1 Receptor AntagonistsReceptors, Neurokinin-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.